A detailed history of Hsbc Holdings PLC transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 16,840 shares of IBRX stock, worth $51,530. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,840
Holding current value
$51,530
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$2.56 - $6.17 $43,110 - $103,902
16,840 New
16,840 $43,000
Q2 2024

Aug 12, 2024

BUY
$4.82 - $9.15 $4,815 - $9,140
999 Added 9.47%
11,545 $72,000
Q1 2024

May 15, 2024

BUY
$3.23 - $6.17 $34,063 - $65,068
10,546 New
10,546 $56,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.22B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.